149 related articles for article (PubMed ID: 36536048)
1. Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090).
Green HD; Merriel SWD; Oram RA; Ruth KS; Tyrrell J; Jones SE; Thirlwell C; Weedon MN; Bailey SER
Br J Cancer; 2023 Feb; 128(4):487-488. PubMed ID: 36536048
[No Abstract] [Full Text] [Related]
2. Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis.
Horton RH; Dunlop MG; Houlston RS; Lucassen A; McCartney M; McNeill A; Sud A
Br J Cancer; 2023 Jan; 128(1):1-2. PubMed ID: 36443602
[No Abstract] [Full Text] [Related]
3. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit.
Vickers A; O'Brien F; Montorsi F; Galvin D; Bratt O; Carlsson S; Catto JW; Krilaviciute A; Philbin M; Albers P
BMJ; 2023 May; 381():e071082. PubMed ID: 37197772
[No Abstract] [Full Text] [Related]
4. The need for active surveillance for low risk prostate cancer.
Drost FH; Roobol MJ
Expert Rev Anticancer Ther; 2017 Jun; 17(6):487-489. PubMed ID: 28406334
[No Abstract] [Full Text] [Related]
5. [Current aspects of prostate cancer screening].
Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
[TBL] [Abstract][Full Text] [Related]
6. Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
Klein RJ
BJU Int; 2022 Mar; 129(3):271. PubMed ID: 35297162
[No Abstract] [Full Text] [Related]
7. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
Pathirana T; Hayen A; Doust J; Glasziou P; Bell K
BMJ Open; 2019 Mar; 9(3):e022457. PubMed ID: 30858156
[TBL] [Abstract][Full Text] [Related]
8. Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis.
Vickers AJ
Clin Chem; 2019 Jan; 65(1):39-41. PubMed ID: 30274977
[No Abstract] [Full Text] [Related]
9. Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer.
Walter SD; Hu J; Talala K; Tammela T; Taari K; Auvinen A
Cancer Causes Control; 2021 Nov; 32(11):1299-1313. PubMed ID: 34313874
[TBL] [Abstract][Full Text] [Related]
10. Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis.
McCaffery K; Nickel B; Pickles K; Moynihan R; Kramer B; Barratt A; Hersch J
BMJ Open; 2019 May; 9(5):e026960. PubMed ID: 31122983
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Screening.
Catalona WJ
Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
[TBL] [Abstract][Full Text] [Related]
12. Public health perspective on prostate-specific antigen screening: Implications of overdiagnosis and differences in health insurance systems across countries.
Takahashi T
J Med Screen; 2023 Mar; 30(1):49-50. PubMed ID: 36413434
[No Abstract] [Full Text] [Related]
13. Re: Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
Leveridge M; Siemens DR
Eur Urol; 2022 Oct; 82(4):440. PubMed ID: 35907661
[No Abstract] [Full Text] [Related]
14. Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.
Pashayan N; Duffy SW; Neal DE; Hamdy FC; Donovan JL; Martin RM; Harrington P; Benlloch S; Amin Al Olama A; Shah M; Kote-Jarai Z; Easton DF; Eeles R; Pharoah PD
Genet Med; 2015 Oct; 17(10):789-95. PubMed ID: 25569441
[TBL] [Abstract][Full Text] [Related]
15. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
Kaur D; Ulloa-Pérez E; Gulati R; Etzioni R
Cancer; 2018 Apr; 124(8):1752-1759. PubMed ID: 29370459
[TBL] [Abstract][Full Text] [Related]
16. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
17. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
18. Modern prostate cancer diagnostics reduce overdiagnosis - will they open up for population-based screening?
Bratt O; Lilja H
Scand J Urol; 2021 Dec; 55(6):491-492. PubMed ID: 34605720
[No Abstract] [Full Text] [Related]
19. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
20. Breast, prostate, and thyroid cancer screening tests and overdiagnosis.
Jung M
Curr Probl Cancer; 2017; 41(1):71-79. PubMed ID: 28104314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
